None of the 29 investors followed here reported a position in ADIL in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ADIL trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 15, 2026 | Coastlands Capital LpBeneficial Owner of more than 10% of a Class of Security | Purchase at price 2.65 - 2.75 per share. | 3.2K | $8.69K |
| Jul 9, 2026 | Coastlands Capital LpBeneficial Owner of more than 10% of a Class of Security | Purchase at price 2.70 - 2.79 per share. | 11.8K | $32.64K |
| Jun 28, 2026 | Coastlands Capital LpBeneficial Owner of more than 10% of a Class of Security | Purchase at price 2.60 per share. | 25K | $65.00K |
| Jun 11, 2026 | Davidson MatthewOfficer and Director | Stock Award(Grant) at price 0.00 per share. | 297.5K | — |
| Apr 6, 2026 | Claiborne Cary JChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 38K | — |
| Apr 6, 2026 | Schuyler KevinDirector | Stock Award(Grant) at price 0.00 per share. | 9.2K | — |
| Apr 6, 2026 | Gilliland Robertson H.Director | Stock Award(Grant) at price 0.00 per share. | 9.2K | — |
| Apr 6, 2026 | Goodman TonyChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 26.5K | — |
| Apr 6, 2026 | Shah VinayChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 17.3K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.5 | -51.8 | -29.2 | -14.0 | 55.8 | 6.7 | 30.5 | 72.2 | -30.3 | -18.0 | −40.2% | ||
| 2025 | -17.8 | -4.8 | -20.3 | 9.5 | 0.0 | -56.5 | 46.7 | -13.6 | -7.9 | 0.0 | -11.4 | -29.0 | −78.2% |
| 2024 | -38.7 | 78.9 | -34.8 | 27.8 | -14.7 | -20.7 | -9.6 | -5.8 | 2.0 | 0.0 | 0.0 | 1.0 | −45.7% |
| 2023 | 118.2 | -8.3 | -20.5 | -2.9 | -23.5 | -19.2 | 52.4 | -45.3 | -36.5 | -30.6 | 13.5 | -15.1 | −66.2% |
| 2022 | -23.0 | -1.0 | -2.4 | -29.9 | -10.6 | 6.3 | -51.5 | -16.9 | -35.2 | -14.3 | -10.0 | -18.5 | −91.9% |
| 2021 | 26.5 | 16.7 | -3.6 | -9.1 | 12.3 | 3.2 | -4.3 | 68.0 | 4.6 | -25.2 | -13.4 | -2.9 | +58.8% |
| 2020 | -24.5 | -20.9 | -9.7 | 13.8 | 9.5 | -14.2 | 15.8 | -14.3 | 61.6 | -22.0 | 33.9 | -27.0 | −29.5% |
| 2019 | 6.8 | -34.0 | -5.0 | -23.6 | -29.4 | -9.2 | 7.1 | -8.3 | -8.5 | 2.6 | -6.5 | 66.2 | −52.9% |
| 2018 | -23.0 | -11.4 | -30.8 | 103.2 | 33.3 | +28.0% |
Buy / hold / sell counts
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.